Increased serum levels of mutant p53 proteins in patients with colorectal cancer

Kang Sup Shim, Kwang Ho Kim, Byeong Woo Park, Sun Young Lee, Jin Hyuk Choi, Woon Sup Han, Eung Bum Park

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

We have examined the serum levels of the mutant p53 protein in patients with colorectal cancer preoperatively (n=50), and in patients with adenomatous polyp (n=13). Mutant p53 protein in patients after curative surgical resection of colorectal cancer (n=26, part of the fifty preoperative patients) was also measured. Serum samples were stored frozen at -70°C until the time of analysis. We used the p53 mutant ELISA (QIA03, CALBIOCHEM) system. Serum levels of the mutant p53 protein in patients with colorectal cancer (mean=0.97±0.14 ng/ml, ranged from 0.7 ng/ml to 1.37 ng/ml, n=50) were significantly greater than those in patients with adenomatous polyp (mean=0.73±0.06 ng/ml, ranged from 0.69 ng/ml to 0.83 ng/ml) (p<0.001). There was a significant correlation between serum p53 levels and CA19-9 levels (p<0.01). Serum levels of the mutant p53 protein prior to surgery (mean=0.97±0.13 ng/ml, n=26) significantly decreased after surgical resection of tumor (mean=0.82±0.07 ng/ml) (p<0.001, paired t-test). These results suggest that mutant p53 protein might be used as a potential biomarker in the management of patients with colorectal cancer. Further study is warranted to establish its clinical significance.

Original languageEnglish
Pages (from-to)44-48
Number of pages5
JournalJournal of Korean Medical Science
Volume13
Issue number1
DOIs
StatePublished - Feb 1998

Keywords

  • Colorectal cancer
  • ELISA
  • Mutant p53 protein
  • Serum

Fingerprint

Dive into the research topics of 'Increased serum levels of mutant p53 proteins in patients with colorectal cancer'. Together they form a unique fingerprint.

Cite this